Key Insights from Lucas Chang at Growth Asia Summit 2026
Evolution of Probiotic Delivery
Lucas Chang, R&D Manager at TCI, emphasized the need for probiotics to evolve beyond logistics and focus more on biological challenges. Historically, success was defined by the survival and arrival of the probiotics in the intestine. However, he argues that what happens after arrival is equally crucial, as it influences gut-health interactions across different bodily systems.
Understanding Biological Context
The “evidence chain” in gut-axis science must trace microbiome function, the bioactive compounds produced, the host’s response, and the observable impacts of these interactions. Chang highlighted that without traceability in these steps, correlations may exist, but they don’t establish clear mechanisms which is vital for understanding healthy aging.
Aging and Biological Challenges
Chang discussed how biological decline doesn’t happen at a constant rate. Key disruptions occur in midlife (around 40) and later (around 60), leading to shifts in metabolism, immune regulation, and other significant processes. Understanding these pressure points is essential for addressing aging and maintaining resilience against biological challenges.
TCR711: A Dual-Purpose Probiotic
To tackle common aging-related stresses like fat accumulation and acute alcoholic intake, TCI developed TCR711, a patented strain. Clinical studies demonstrated its effectiveness in reducing liver fat and enhancing gut ecology, indicating its multi-faceted role.
Innovative Delivery in Functional Probiotics
Chang suggested that when designing probiotics, the focus should be on the desired health outcomes. He introduced the innovative idea of delivering probiotics in liquid chocolate, a format that enhances survival rates while integrating seamlessly into daily habits.
Conclusion
The future of probiotics lies in understanding their biological integration and function, moving beyond mere survival to optimizing health outcomes through innovative delivery methods.
